Lepu Medical

Lepu Medical Technology (Beijing) Co., LTD. ("Lepu Medical" for short) was founded in 1999 and is one of the earliest enterprises in China to engage in the research, development, and manufacturing of interventional cardiology medical devices. Over the past 20 years, the company has consistently focused on serving cardiovascular patients comprehensively, driving high-quality development through innovation. It has now become a leading platform in China's cardiovascular healthcare industry, with core businesses covering three major sectors: medical devices, pharmaceuticals, medical services, and health management. The company has been designated as the "National Engineering Research Center for Cardiovascular Interventional Diagnosis and Treatment Devices and Equipment" by the Ministry of Science and Technology of China. Lepu Medical’s independently developed products, including bioresorbable stents, cutting balloons, drug-coated balloons, degradable occluders, TAVR valves, and artificial intelligence-based automatic ECG analysis and diagnostic systems, have reached internationally advanced levels. In the future, Lepu Medical will continue to uphold its mission of "wholeheartedly serving cardiovascular patients." On the foundation of providing full lifecycle services that include disease prevention, diagnosis, medication treatment, surgical treatment, postoperative rehabilitation, chronic disease management, and secondary prevention, the company will further increase technological innovation and actively expand into strategic emerging industries such as AI healthcare. While striving to provide advanced and high-quality products and services to a broad patient base, Lepu Medical will continuously drive technological advancement and industrial upgrading within the sector. Adhering to the principle of staged development—“pre-research one generation, register one generation, and produce/sell one generation”—the company has evolved from coronary drug-eluting stents to the era of bioresorbable medical devices and AI-powered intelligent medical devices. Lepu Medical boasts key products like NeoVas, the internationally recognized second-generation bioresorbable stent, and Vesselin, a new-generation intravascular paclitaxel drug-eluting balloon catheter. Its AI-ECG software system, which uses internationally leading artificial intelligence technology for ECG analysis, has received approval from the U.S. FDA, EU CE certification, and NMPA registration. The company also offers a range of technologically distinctive products, including coronary drug-eluting stents, balloons, pacemakers, occluders, heart valves, angiography machines, IVD equipment and diagnostic reagents, surgical instruments, AI-based ECG devices, and home-use smart medical devices. In 2020, Hefei High-Tech Cardiovascular Hospital (Gaoxin Hospital), controlled by the company, was approved by the Anhui Provincial Health Commission to establish an "Internet Hospital." Looking ahead, Lepu Medical will continue to enhance its full-lifecycle industrial platform for the prevention, diagnosis, treatment, and rehabilitation of cardiovascular diseases. The company aims to create a specialized ecosystem that integrates "cardiovascular healthcare and oncology," providing advanced products and high-quality services to more patients suffering from cardiovascular and cancer-related conditions.